Schechter Investment Advisors LLC Lowers Stock Holdings in Grifols, S.A. (NASDAQ:GRFS)

Schechter Investment Advisors LLC reduced its position in Grifols, S.A. (NASDAQ:GRFS) by 9.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 88,245 shares of the biotechnology company’s stock after selling 9,154 shares during the period. Schechter Investment Advisors LLC’s holdings in Grifols were worth $1,020,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GRFS. Advisor Group Holdings Inc. grew its stake in Grifols by 16.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 11,574 shares of the biotechnology company’s stock worth $135,000 after acquiring an additional 1,619 shares during the period. Raymond James & Associates acquired a new position in shares of Grifols in the 1st quarter valued at $158,000. US Bancorp DE boosted its holdings in shares of Grifols by 21.7% in the 1st quarter. US Bancorp DE now owns 35,857 shares of the biotechnology company’s stock valued at $418,000 after purchasing an additional 6,393 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Grifols by 40.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,530 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 3,010 shares during the last quarter. Finally, BlackRock Inc. boosted its holdings in shares of Grifols by 30.9% in the 1st quarter. BlackRock Inc. now owns 2,506,483 shares of the biotechnology company’s stock valued at $29,276,000 after purchasing an additional 591,834 shares during the last quarter.

Grifols Trading Up 2.6 %

Grifols stock opened at $6.65 on Thursday. Grifols, S.A. has a 12-month low of $5.30 and a 12-month high of $12.15. The company has a quick ratio of 1.32, a current ratio of 2.83 and a debt-to-equity ratio of 1.24. The firm’s fifty day moving average price is $7.50 and its 200 day moving average price is $8.71.

Analyst Upgrades and Downgrades

GRFS has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft lowered shares of Grifols from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th. JPMorgan Chase & Co. lifted their target price on shares of Grifols from $10.00 to $10.50 and gave the company a “neutral” rating in a report on Tuesday, December 5th.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product.